Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Depakote ER Approved for Bipolar Indication

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Extended-release Depakote now carries the same indications as twice-daily Depakote.

You may also be interested in...



Mail-Order Pharmacy Not Necessarily Cheaper To Health Plans, Ohio Finds

Health plans should account for the rise in utilization that occurs with use of mail-order pharmacy when deciding if mail order saves money, Ohio Public Employees Retirement System Director of Healthcare Scott Streator said at the recent Academy of Managed Care Pharmacy Educational Conference in Chicago

Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says

Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says

Pfizer Cost-Cutting: Details Are Sketchy, But Sales Force Is On The Table

Pfizer CEO Jeffrey Kindler has opened the door to sales force reductions as part of the firm's latest cost-cutting initiative, announced Oct. 1

Table

View full table

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By